Neuren Pharmaceuticals Ltd has released a press release.
Q2 2021 quarterly activity and cash flow report
Filed with ASX ·
6ix hasn’t read this filing yet.
Neuren Pharmaceuticals Limited on 6ix
Earlier from Neuren Pharmaceuticals
- Positive FDA meetings enable INDs for three Phase 2 trials
- New patent issued to 2032 for Neurens trofinetide in Canada
- Quarterly report and cash flow statement for Q1 2021
- S&P DJI Announces March 2021 Quarterly Rebalance
- Neuren successfully completes manufacturing for Phase 2
Later from Neuren Pharmaceuticals
- Phase 3 enrolment successfully completed, results in Q4 2021
- R&D Tax Incentive Advance Overseas Finding Approval
- Angelman IND and Ethics applications submitted for NNZ-2591
- FDA grants Orphan Drug designation for Prader-Willi syndrome
- Placement to accelerate NNZ-2591 across 4 indications
Follow Neuren Pharmaceuticals into a list and get an email when it puts out news.
Follow Neuren Pharmaceuticals